EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care

Laurel H Messer iD, Marc D Breton iD

Diabetes Technology & Therapeutics · 2023

DOI: 10.1089/dia.2023.0308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Laurel H Messer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Tandem Diabetes Care, San Diego, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine insulin dosing parameters that are associated with and predict optimal outcomes for people using t:slim X2 with Control-IQ technology (CIQ).

Methods

Retrospective deidentified data from CIQ users were analyzed to determine the effect of Correction Factor, Carbohydrate-to-Insulin (C:I) Ratio, and basal rate settings (standardized by total daily insulin [TDI]) on glycemic control. We performed an associative analysis followed by linear regressions to determine the relative importance of the settings and confounding variables (e.g., age or number of user-initiated boluses) in predicting consensus glycemic outcomes.

Results

Data from 20,764 individuals were analyzed (median age 39 years [interquartile range 19, 59], 55% female, TDI 46.4 U [33–65.2]). More aggressive Correction Factor settings, C:I ratio settings, and basal programs were all strongly associated with higher time in range (TIR, 70–180 mg/dL) and to a lesser degree to higher time

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HypoglycemiaHumansFemaleAdultMaleHypoglycemic AgentsBlood GlucoseRetrospective StudiesBlood Glucose Self-MonitoringInsulin Infusion SystemsInsulinInsulin, Regular, HumanTechnology

Stichwörter der Autor:innen

Automated insulin deliveryDiabetes technologyHybrid closed loopInsulin pumpType 1 diabetes

Substanzen

Hypoglycemic AgentsBlood GlucoseInsulinInsulin, Regular, Human

Autor:innen und Institutionen

  • Tandem Diabetes Care, San Diego, California, USA.
  • Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Laurel H Messer, Marc D Breton

Zitieren

APA

Messer, L. H., & Breton, M. D. (2023). Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0308

Vancouver

Messer LH, Breton MD. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2023.0308

BibTeX
@article{Messer2023,
  author = {Messer, Laurel H and Breton, Marc D},
  title = {Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  doi = {10.1089/dia.2023.0308}
}
Kostenlos starten →